ABSTRACT
Background. Optimal lymphocyte parameters and thresholds for the diagnosis of chronic lymphocytic leukemia have been proposed by The National Cancer Institute-sponsored Working Group and recently updated by the International Workshop on chronic lymphocytic leukemia. However, it is not clear how these criteria apply to the management of patients in the daily clinical practice and whether the lymphocyte thresholds recommended truly predict for clinical outcome in early chronic lymphocytic leukemia.
Design and Methods. An observational database of the GIMEMA (Gruppo Italiano
Malattie Ematologiche dell'Adulto), which included 1158 patients with newly diagnosed Binet stage A chronic lymphocytic leukemia who were observed at different primary hematology centers during the period 1991-2000, was used for the purpose of this study.
Results. Among 818 consecutive chronic lymphocytic leukemia patients with Rai stage 0 (i.e., no palpable lymphadenopathy or hepatosplenomegaly) who had flow cytometry evaluations at the time of diagnosis and were included in a GIMEMA database, both absolute lymphocyte count and B-cell count had a similar value in predicting time to first treatment as continuous variables (P<0.0001). Receiver operating characteristic analysis identified an absolute lymphocyte count of 11.5x10 9 /L and an absolute B-cell count of 10.0x10 9 /L as the best thresholds capable of separating patients who will require treatment from those with stable disease. However, in a Cox multivariate analysis only the B-cell count retained its discriminating power (P<0.0001) and the estimated rate of progression to chronic lymphocytic leukemia requiring treatment among subjects with a B-cell count <10.0x10 9 /L was approximately 2.3% per year (95% CI, 2.1-2.5%) while it was two-fold higher for patients with a B-cell count ≥10.0x10 9 /L (i.e., 5.2% per year; 95% CI=4.9-5.5%).
Finally, in this community-based patient cohort the B-cell threshold defined by DOI: 10.3324/haematol.2010.030189 investigators at the Mayo Clinic (i.e., 11.0x10 9 /L) allowed to separate patients into two subsets with a higher and lower likelihood of treatment ( P<0.0001).
Conclusions.
Our results, based on a retrospective patients' cohort, provide a clear justification to retain the B-cell count as the reference gold standard of chronic lymphocytic leukemia diagnosis and imply that a count of 10x10 9 /L B cells is the best lymphocyte threshold to predict time to first treatment. The use of clinical outcome to distinguish chronic lymphocytic leukemia from other premalignant conditions, such as monoclonal Bcell lymphocytosis, is a pragmatic approach meeting the patients' need to minimize the psychological discomfort of receiving a diagnosis of leukemia when the risk of adverse clinical consequences is low.
INTRODUCTION
The incidence and presenting features of chronic lymphocytic leukemia (CLL) have changed significantly in the last thirty years (1) (2) (3) . Both the introduction of automated blood counters in the routine clinical practice and the evolution of flow cytometry have led to a lowering of the absolute lymphocyte count (ALC) required for a diagnosis of CLL (i.e.
≥5.0x10
9 /L) (4) . In addition, the sensitivity of these diagnostic procedures has allowed the identification of a new clinical entity defined monoclonal B-cell lymphocytosis (MBL), whose natural history is not yet conclusively defined (5, 6) .
From a clinical standpoint, the development of formal criteria for the diagnosis of MBL proposed in 2005 guided the 2008 revisions of minimal requirements for CLL diagnosis (7) .
Briefly, the new criteria recommend to use the B-cell count rather than the ALC as a basis for the diagnosis of CLL and suggest a B-cell threshold of 5.0x10 9 /L to distinguish CLL from MBL (7) .
However, the B-cell threshold for the diagnosis of CLL was arbitrarily selected and was not based on objective data of clinical outcome. Given the seriousness of a diagnosis of leukemia and the evolution of the diagnostic criteria of CLL, information on how the quantitative evaluation of the B-cell clone relates to the clinical outcome of the disease appears mandatory. Recently, the Mayo Clinic Group looked at the correlation between diagnostic lymphocyte parameters and the clinical outcome in a cohort of Rai stage 0 patients who had molecular markers available and whose follow-up information allowed an association with either time to first treatment (TFT) or overall survival (OS) (8, 9) .
In order to contribute to this debate and possibly to confirm these observations, the 
DESIGN AND METHODS

Patients
The GIMEMA CLL database includes previously untreated CLL patients in (4, 10) . 
Indication for therapy
Patients underwent sequential monitoring and the frequency of follow-up visits was individualized according to patients' risk. In detail, it ranged between 3 and 12 months (median, 6 months). All physicians who registered patients into this observational GIMEMA database stated that they had used the NCI-WG guidelines as a reference criteria for starting therapy (4, 10) . In detail, the absolute lymphocyte count was not used as the sole indicator for treatment. Active disease, requiring therapy, was defined on the basis of at least one of the following criteria (4) .
Statistical analysis
TFT was defined as the time between the date of diagnosis and the date of initiation of first treatment or the date of the last follow-up at which the patient was known to be untreated.
Estimates of TFT were calculated using the Kaplan-Meier method. To test effects of individual factors, either in univariate analysis or jointly, likelihood ratio tests were used.
Hazard ratios (HR) and confidence intervals (CI) for HRs were calculated from the Cox models. Determination of optimal thresholds for ALCs and B-cell counts relating to TFT was performed using the receiver operating characteristic (ROC) analysis. The area under the ROC curve (AUC) can range from 0.5, which indicates a test with no information, to 1.0, which indicates a perfect test. Because HR calculates the magnitude of risk rather than the model's capacity to accurately classify patients' outcome, Harrell's C-statistics were used to further evaluate the discriminatory power of lymphocyte variables in terms of TFT (11) . /L, respectively) (6, 9) . While ALC and B-cell count were strongly correlated for the overall cohort of patients (r=0.938; P<0.0001) (Figure 1a ), no correlation between ALC and B-cell count were observed when the analysis was restricted to subjects with a B-cell count lower than 5. /L. These observations, similar to those reported by Shanafelt et al (8) , led to retain that absolute CD19 positive B-cell may be considered a reliable surrogate of clonality in this subset of patients.
RESULTS
Among
Since the B-cell threshold proposed in the 2008 CLL diagnostic criteria (7) to differentiate MBL from CLL (i.e., 5x10 A graphic representation on how these thresholds work in predicting TFT is presented in Figures 4 /L (i.e., 5.2% per year; 95% CI=4.9-5.5%).
Finally, we wondered whether the B-cell threshold identified by investigators at the Mayo Clinic (i.e., 11.0x10 9 /L) (8) was applicable to the patient series included in the GIMEMA database. In this community-based patient cohort, used as a test-set series, we clearly confirmed that the threshold identified by Shanafelt el al (8) allowed to separate patients into two subsets with a higher and a lower likelihood of treatment, respectively (HR, 2.26; 95% CI=1.61-3.18; P<0.0001) ( Figure 6 ).
DISCUSSION
The diagnosis of asymptomatic CLL has been based on the presence of an expanded monoclonal B-cell clone and an increased ALC. Although the immunophenotypic evaluation of subjects with an absolute lymphocytosis is generally easy in the era of flow cytometry, no definitive prospective or retrospective lymphocyte threshold information useful to establish a diagnosis of CLL is available. (12) Our findings, based on a large community-based cohort of patients who underwent evaluation for an asymptomatic lymphocytosis in different Italian hematological institutions referring to the GIMEMA, basically confirm the observations of Shanafelt et al., (8) .
This proposed change has however some shortcomings, such as the absence of a standardized way to measure B-cell counts. Flow cytometric immunophenotyping for leukemia/lymphoma analysis is not a quantitative test and no standardized approach for determining B-cell counts in CLL has been proposed (13) . On the other hand, the method used for B-cell count measurement in patients included in the GIMEMA multicenter database is less accurate in comparison to the method utilized in the Mayo Clinic studies (8, 9) . These technical differences, that reflect the absence of an immunophenotypic centralization in the GIMEMA series, translate into a slight variation in B-cell thresholds between the two series. Furthermore, a shift from an ALC to a B-cell count could imply repeated flow cytometric analyses to monitor the outcome of CLL. The relationship between B-cell count and ALC hereby reported (Fig. 1a) , essentially in patients with a diagnosis of CLL, suggests that a reasonable practical approach would be to monitor the ALC in patients with a B-cell count above the diagnostic threshold (i.e., ≥5.0 x 10 9 /L Blymphocytes) and to reserve periodic B-cell assessments by flow cytometry to patients with MBL until the CLL diagnostic threshold is attained.
The diagnostic criteria for MBL were intended to identify individuals with an abnormal Bcell population in the peripheral blood, but who did not meet the current criteria for a B-cell lymphoproliferative disorder (6, 8, 9, (14) (15) (16) . In a recent study, Rawstron et al. (6) reported the clinical outcome of a cohort of 185 CLL-type MBL cases observed over a 6.7-year period.
The B-cell count (< or ≥1.9x10 9 /L) at the time of the diagnosis of MBL was the only factor independently associated with progressive lymphocytosis; however, no association with OS or TFT was reported. Shanafelt et al (9) described a lower likelihood of treatment requirement for patients with a MBL in comparison to patients with Rai stage 0 CLL. These findings can be due, at least in part, to the lower median absolute B-cell count at the time of diagnosis (2. A limitation of our study is the lack of biologically-based prognostic parameters, which
were not always evaluated at the time of diagnosis. This prevented us from performing a comprehensive multivariate analysis that included all these variables. Although Shanafelt et al (8) demonstrated that the B-cell count remained an independent predictor of TFT even after checking for ZAP-70, CD38, IgVH or fluorescence in situ hybridization (FISH), the prognostic independence of the size of the B-cell count should be validated in an independent series of patients prospectively monitored. On the contrary, one specific strength of this report, when compared to the studies of Shanafelt et al (8, 9) , is represented by the characteristics of our patient cohort that derives from "primary" hematology clinics;
as a consequence, there is no concern of referral/ascertainment bias as in the Mayo Clinic studies.
In conclusion, our results, although based on a retrospective patient series, provide a clear justification to retain the B-cell count as the reference gold standard of CLL diagnosis, but imply that a B-cell count of 10.0x10 9 /L represents the threshold that best predicts TFT.
From a clinical standpoint, an international and integrated clinical observational study including patients with CLL in early stage -from the time of first presentation -and followed prospectively to better define the fate of the disease should conclusively address the issue. This is crucial to minimize unneeded psychological discomfort caused by labeling individuals with laboratory abnormalities and/or low risk clinical features as having leukemia (18) .
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